Fennec Pharmaceuticals Inc.

9.31 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Fennec Pharmaceuticals Inc. stock is up 22.18% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 69.23% of the previous 12 December’s closed higher than November.

About Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. develops product candidates for use in the treatment of cancer in the U.S. Its lead product PEDMARK is a formulation of Sodium Thiosulfate that has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.